Previously, we outlined New York Governor Kathy Hochul’s proposed 2023-2024 New York State Budget (“Proposed Budget”) and how it may impact the healthcare deal landscape in New York. Specifically, we discussed proposed amendments to Part L of... Read More
Frier Levitt has recently become aware that the New Jersey Department of Health (NJDOH) has been issuing notices to medical practices and other facilities that may offer Platelet-Rich Plasma (PRP) injections to patients for non-surgical purposes –... Read More
After DEA’s of its draft temporary rule last week, the Drug Enforcement Administration (“DEA”) has officially published a temporary rule expanding COVID-19 related flexibilities for prescribing controlled substances via telehealth. The... Read More
Beginning in March 2020 with the shutdown orders effectuated by Governor Phil Murphy, the various licensing boards organized under the State of New Jersey, Division of Consumer Affairs, experienced a significant decrease in activity. The state was... Read More
Last month, HHS Office for Civil Rights (“OCR”) announced that its COVID-19 related enforcement discretion regarding the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) will end on May 11, 2023, coinciding with the... Read More
While the survival and enforceability of noncompete agreements remain uncertain, those that exist are still being challenged, and courts are scrutinizing the language contained therein. Courts have routinely enforced noncompete agreements that were... Read More
Frier Levitt attorneys speak with prosecutors, Boards of Pharmacies, PBM auditors, wholesalers, and the like on a daily basis on behalf of pharmacies nationally. We regularly spot trends and report back to the industry. We are closely monitoring... Read More
The Federal Trade Commission (“FTC”) recently enforced its Health Breach Notification Rule (“Rule”) for the very first time. The FTC issued a $1.5 million civil penalty to GoodRx and imposed restrictions on the company’s future handling of... Read More
On February 22, 2023, the U.S. Department of Justice (“DOJ”) issued a corporate Voluntary Self-Disclosure policy (the “Policy”) that applies to all United States Attorney’s Offices (“USAOs”), effective immediately. The articulated goal... Read More
A staple of Medicare and False Claims Act (“FCA”) law – the so-called “Overpayment Rule” – may soon be undergoing a dramatic shift, and doing so in a way that could increase liability for healthcare providers while potentially reducing... Read More
